That could benefit Cephalon (nasdaq: CEPH - news - people ), of Frazer, Pa.
As drizzle falls on Cephalon's ceph (nasdaq: ceph - news - people) offices in West Chester, Pa.
Cephalon (nasdaq: CEPH - news - people ) sells a drug called Trisenox to treat a form of leukemia.
Englander is also interested in Cephalon (nasdaq: CEPH - news - people ), whose formulation Provigal has been approved for use in treating narcolepsy.
But some epilepsy medicines, including Neurontin from Pfizer and Gabitril from Cephalon (nasdaq: CEPH - news - people ), may also help slow wave sleep.
Side effects were the main reason for an FDA advisory panel's March 23 vote against Cephalon 's (nasdaq: CEPH - news - people ) Sparlon.
But its maker, Cephalon (nasdaq: CEPH - news - people ), says that 80% of prescriptions are probably written out to people who are tired for other reasons, not narcoleptics.
For instance, one settlement with multiple generic firms is expected to give biotech Cephalon (nasdaq: CEPH - news - people ) several extra years of sales of its wakefulness drug Provigil.
Cephalon (nasdaq: CEPH - news - people ) has a patent protecting the way Provigil is made until 2014, but four generic companies are arguing either that the patent is invalid or that it doesn't apply to their versions.
In summer 2000, a small biotechnology company called Cephalon (nasdaq: CEPH - news - people ) saw its stock plummet more than 35% for good reason, as investors freaked out over a study that said the company's biggest drug, Provigil, was not effective against Attention Deficit Hyperactivity Disorder (ADHD).
Traditionally, doctors have had to treat all these symptoms individually, giving patients a stimulant like Cephalon 's (nasdaq: CEPH - news - people ) Provigil or Novartis ' (nyse: NVS - news - people ) Ritalin to stave off sleepiness and then adding an antidepressant to try to prevent cataplexy.
Arena was founded in San Diego by Lief, a veteran drug executive with experience at Abbott and Cephalon (nasdaq: CEPH - news - people ), and researchers Dominic Behan and Derek Chalmers, who had both left San Diego biotech Neurocrine Biosciences (nasdaq: NBIX - news - people ) to pursue novel ideas about drug development.
应用推荐